Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 4 studies | 44% ± 12% | |
type II pneumocyte | 3 studies | 24% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 21% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 7092.09 | 226 / 226 | 98% | 82.39 | 399 / 406 |
lung | 99% | 498.03 | 574 / 578 | 80% | 22.65 | 926 / 1155 |
thymus | 99% | 252.85 | 645 / 653 | 73% | 4.68 | 440 / 605 |
pancreas | 99% | 292.34 | 325 / 328 | 70% | 4.33 | 125 / 178 |
breast | 99% | 355.25 | 456 / 459 | 47% | 7.44 | 528 / 1118 |
stomach | 91% | 114.14 | 325 / 359 | 41% | 3.05 | 118 / 286 |
ovary | 100% | 860.99 | 180 / 180 | 25% | 1.70 | 109 / 430 |
intestine | 75% | 91.88 | 722 / 966 | 42% | 2.96 | 221 / 527 |
uterus | 78% | 122.08 | 133 / 170 | 29% | 2.24 | 135 / 459 |
adrenal gland | 77% | 122.70 | 198 / 258 | 25% | 4.40 | 58 / 230 |
adipose | 96% | 171.56 | 1154 / 1204 | 0% | 0 | 0 / 0 |
bladder | 67% | 144.43 | 14 / 21 | 28% | 4.35 | 143 / 504 |
esophagus | 51% | 45.11 | 733 / 1445 | 43% | 3.51 | 79 / 183 |
brain | 65% | 77.06 | 1716 / 2642 | 21% | 0.68 | 150 / 705 |
skin | 73% | 303.73 | 1316 / 1809 | 13% | 1.00 | 62 / 472 |
prostate | 66% | 76.98 | 162 / 245 | 1% | 0.02 | 4 / 502 |
heart | 62% | 72.26 | 534 / 861 | 0% | 0 | 0 / 0 |
kidney | 35% | 30.48 | 31 / 89 | 10% | 0.58 | 86 / 901 |
tonsil | 0% | 0 | 0 / 0 | 42% | 4.02 | 19 / 45 |
spleen | 28% | 34.85 | 68 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 15% | 0.99 | 12 / 80 |
muscle | 14% | 10.32 | 111 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 11% | 11.11 | 148 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 2.51 | 12 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_2001038 | Biological process | regulation of cellular response to drug |
GO_0009636 | Biological process | response to toxic substance |
GO_0003096 | Biological process | renal sodium ion transport |
GO_1901335 | Biological process | lactone catabolic process |
GO_0032929 | Biological process | negative regulation of superoxide anion generation |
GO_0051649 | Biological process | establishment of localization in cell |
GO_0046395 | Biological process | carboxylic acid catabolic process |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0004063 | Molecular function | aryldialkylphosphatase activity |
GO_0102007 | Molecular function | acyl-L-homoserine-lactone lactonohydrolase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0004064 | Molecular function | arylesterase activity |
Gene name | PON3 |
Protein name | Serum paraoxonase/lactonase 3 (EC 3.1.1.2) (EC 3.1.1.81) (EC 3.1.8.1) Paraoxonase 3 Paraoxonase (EC 3.1.1.2) |
Synonyms | |
Description | FUNCTION: Has low activity towards the organophosphate paraxon and aromatic carboxylic acid esters. Rapidly hydrolyzes lactones such as statin prodrugs (e.g. lovastatin). Hydrolyzes aromatic lactones and 5- or 6-member ring lactones with aliphatic substituents but not simple lactones or those with polar substituents. . |
Accessions | ENST00000265627.10 F8WBV4 ENST00000451904.5 ENST00000442770.5 ENST00000427422.5 C9JZ99 F2Z2L3 Q15166 ENST00000456855.5 ENST00000418617.5 F8WD41 |